Operative Therapiestrategien bei der Frau mit Mammakarzinom

M. P. Lux; C. C. Hack; M. R. Bani; S. M. Jud; P. Kern; M. Friedrich; S. Krämer; M. W. Beckmann; M. Rezai

doi:10.1055/s-0031-1283999

Frauenheilkunde up2date, Inhaltsverzeichnis

Frauenheilkunde up2date 2012; 6(2): 73-95
DOI: 10.1055/s-0031-1283999

Allgemeine Gynäkologie und gynäkologische Onkologie

Operative Therapiestrategien bei der Frau mit Mammakarzinom

M. P. Lux

¹Frauenklinik, Universitätsklinikum Erlangen

,

C. C. Hack

¹Frauenklinik, Universitätsklinikum Erlangen

,

M. R. Bani

¹Frauenklinik, Universitätsklinikum Erlangen

,

S. M. Jud

¹Frauenklinik, Universitätsklinikum Erlangen

,

P. Kern

¹Frauenklinik, Universitätsklinikum Erlangen

,

M. Friedrich

¹Frauenklinik, Universitätsklinikum Erlangen

,

S. Krämer

¹Frauenklinik, Universitätsklinikum Erlangen

,

M. W. Beckmann

¹Frauenklinik, Universitätsklinikum Erlangen

,

M. Rezai

¹Frauenklinik, Universitätsklinikum Erlangen

› Institutsangaben

Abstract

Alle Artikel dieser Rubrik

Volltext

Referenzen

Literatur
1 Katalinic A. Breast cancer: declining mortality despite its increasing incidence. Geburtsh Frauenheilk 2009; 69: 237-239
2 Kaufmann M, Rody A. Breast cancer: reduced mortality by early detection and adjuvant therapy. Geburtsh Frauenheilk 2009; 69: 218-232
3 Beckmann MW, Brucker C, Hanf V et al. Quality assured health care in certified breast centers and improvement of prognosis of breast cancer patients. Onkologie 2011; 34: 362-367
4 Lux MP, Fasching PA, Bani MR et al. Marketing of breast and perinatal centers are patients familiar with the product “Specialized Centers and Certification”?. Geburtsh Frauenheilk 2009; 69: 321-327
5 Lux MP, Fasching PA, Loehberg CR et al. Health services research and health economy – quality care training in gynaecology, with focus on gynaecological oncology. Geburtsh Frauenheilk 2011; 71 [in press]
6 Lux MP, Fasching PA, Schrauder M et al. The age of centers: the influence of establishing specialized centers on patients’ choice of hospital. Arch Gynecol Obstet 2011; 283: 559-568
7 Lux MP, Hildebrandt T, Bani MR et al. Gesundheitsökonomische Aspekte und finanzielle Probleme in den zertifizierten Strukturen des Fachgebietes. Gynäkologe 2011; 44: 816-826
8 Kreienberg R, Kopp I, Albert U et al. Interdisziplinäre S3-Leitlinie – Diagnostik, Therapie und Nachsorge beim Mammakarzinom. Munich: W. Zuckschwerdt Verlag; 2008
9 Wöckel A, Varga D, Atassi Z et al. Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study. Onkologie 2010; 33: 21-28
10 Liedtke C, Wolf MK, Kiesel L. New concepts for targeted systemic therapy in breast cancer. Geburtsh Frauenheilk 2010; 70: 625-633
11 Pfandzelter R, Wulfing U, Boedeker B et al. Diagnostic image quality of mammograms in German outpatient medical care. Geburtsh Frauenheilk 2010; 70: 998-1005
12 Kümmel S, Kolberg HC, Lüftner D et al. Mammakarzinom 2011 – neue Aspekte. Geburtsh Frauenheilk 2011; 71 [in press]
13 Du BoisA, Miselwitz B, Stillger R et al. Versorgungsstruktur und Qualität bei der Behandlung des Mammakarzinoms. Eine Untersuchung am Beispiel Daten aus Hessen 1996–2002. Geburtsh Frauenheilk 2003; 63: 743-751
14 Hershman DL, Neugut AI, Richards CA et al. Influence of hospital factors, physician factors and type of health insurance on receipt of immediate postmastectomy reconstruction in young women with breast cancer. Cancer Res 2011; 71: 114s-115s
15 Bauerfeind I, Kümmel S. Operatives Vorgehen unter onkologischen Aspekten. In: Kommission Mamma (vertreten durch Anton Scharl), Arbeitsgemeinschaft Gynäkologische Onkologie e. V., Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V., Deutsche Krebsgesellschaft e. V. Aktuelle Empfehlungen zur Therapie primärer und fortgeschrittener Mammakarzinome State of the Art 2011. München: W. Zuckschwerdt Verlag; 2011: 103-117
16 Wallis M, Tardivon A, Helbich T et al. Guidelines from the European Society of Breast Imaging for diagnostic interventional breast procedures. Eur Radiol 2007; 17: 581-588
17 Houssami N, Ciatto S, Macaskill P et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008; 26: 3248-3258
18 Bedrosian I, Mick R, Orel SG et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 2003; 98: 468-473
19 Lord SJ, Lei W, Craft P et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007; 43: 1905-1917
20 Morrow M, Venta L, Stinson T et al. Prospective comparison of stereotactic core biopsy and surgical excision as diagnostic procedures for breast cancer patients. Ann Surg 2001; 233: 537-541
21 Arbeitgemeinschaft Gynäkologische Onkologie e. V. Kommission Mamma. Diagnostik und Therapie primärer und metastasierter Mammakarzinome. Version 2011 www.ago-online.de
22 von Minckwitz G, Blohmer JU, Costa S et al. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients – results of the GeparTrio Trial. Cancer Res 2011; 71: 103s
23 Lux MP, Schütz F. Neoadjuvante systemische Therapie des Mammakarzinoms. In: Kommission Mamma (vertreten durch Anton Scharl), Arbeitsgemeinschaft Gynäkologische Onkologie e. V., Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V., Deutsche Krebsgesellschaft e. V. Aktuelle Empfehlungen zur Therapie primärer und fortgeschrittener Mammakarzinome State of the Art 2011. München: W. Zuckschwerdt Verlag; 2011: 103-117
24 Buchholz TA, Lehman CD, Harris JR et al. Statement of the science concerning locoregional treatments after preoperative chemo-therapy for breast cancer: a National Cancer Institute conference. J Clin Oncol 2008; 26: 791-797
25 Chia S, Swain SM, Byrd DR et al. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008; 26: 786-790
26 Dawood S, Ueno NT, Cristofanilli M. The medical treatment of inflammatory breast cancer. Semin Oncol 2008; 35: 64-71
27 Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 188-194
28 Mieog JSD, van der Hage JA, van de Velde CJH. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database of Systematic Reviews. Issue 2007 Art. No.: DC005002 2.
29 Oh JL, Dryden MJ, Woodward WA et al. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol 2006; 24: 4971-4975
30 Marret H, Perrotin F, Bougnoux P et al. Histologic multifocality is predictive of skin recurrences after conserving treatment of stage I and II breast cancers. Breast Cancer Res Treat 2001; 68: 1-8
31 Cho LC, Senzer N, Peters GN. Conservative surgery and radiation therapy for macroscopically multiple ipsilateral invasive breast cancers. Am J Surg 2002; 183: 650-654
32 Dawood S, Merajver SD, Viens P et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011; 22: 515-523
33 Wallwiener D, Jonat W, Kreienberg R et al. Atlas der gynäkologischen Onkologie. Stuttgart: Georg Thieme Verlag; 2009: 671-677
34 Kaufmann M, Hortobagyi GN, Goldhirsch A et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24: 1940-1949
35 von Minckwitz G, Rezai M, Loibl S et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin / cyclophosphamide docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG / AGO intergroup-study GeparQuattro. Breast Cancer Res Treat 2007; 106: 79
36 von Minckwitz G, Kümmel S, Vogel P. German Breast Group et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008; 100: 552-562
37 von Minckwitz G, Kümmel S, Vogel P et al. Inflammatory and locally advanced breast cancer respond similar to operable breast cancer to neoadjuvant chemotherapy: Results from the GeparTrio study. J Clin Oncol 2007; 25: 542
38 Goyal A, Douglas-Jones A, Monypenny I et al. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ? Analysis of 587 cases. Breast Cancer Res Treat 2006; 98: 311-314
39 Wiatrek R, Kruper L. Sentinel lymph node biopsy indications and controversies in breast cancer. Maturitas 2011; 69: 7-10
40 Giuliano AE, Dale PS, Turner RR et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222: 394-399
41 Veronesi U, Viale G, Paganelli G et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010; 251: 595-600
42 Kim HJ, Lee JS, Park EH et al. Sentinel node biopsy in patients with multiple breast cancer. Breast Cancer Res Treat 2008; 109: 503-506
43 Classe JM, Bordes V, Campion L et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009; 27: 726-732
44 Kuerer HM, Newman LA. Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies. J Clin Oncol 2005; 23: 1698-1705
45 Weaver DL, Krag DN, Ashikaga T et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000; 88: 1099-1107
46 Weaver DL, Krag DN, Manna EA et al. Detection of occult sentinel lymph node micrometastases by immunohistochemistry in breast cancer. An NSABP protocol B-32 quality assurance study. Cancer 2006; 107: 661-667
47 Cote R, Giuliano AE, Hawes D et al. ACOSOG Z00100: a multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastasis in women with clinical T1 / T2 N0 M0 breast cancer. J Clin Oncol 2010; 28: 18s
48 Giuliano AE, McCall L, Beitsch P et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 252: 426-432
49 Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006; 106: 4-16
50 Cox CE, Salud C, Whitehead GF et al. Sentinel lymph node biopsy for breast cancer: combined dye-isotope technique. Breast Cancer 2000; 7: 389-397
51 Axelsson CK, Düring M, Christiansen PM . Danish Breast Cancer Cooperative Group Surgical Study Group et al. Impact on regional recurrence and survival of axillary surgery in women with node-negative primary breast cancer. Br J Surg 2009; 96: 40-46
52 Rezai M, Kern P. Neue Operative Methoden der Brustchirurgie – Probleme und deren mögliche Lösungen. J Ästhet Chir 2012; 5: 29-36
53 Rezai M et al. Skin Sparing Mastectomy (SSM) and Immediate Breast Reconstruction (IBR) – Innovating techniques with titanized mesh (Tiloop BraR). 6. Europäische Konferenz „Onkoplastik und Rekonstruktive Chirurgie der Brust“, 14.–17.12.2011. Mailand: 2011
54 Kern P, Darsow M, Rezai M, Krämer S. Adjuvante Strahlentherapie und Brustrekonstruktion – was müssen wir beachten?. 10. Jahrestagung der Arbeitsgemeinschaft für ästhetische und wiederherstellende Operationsverfahren in der Gynäkologie e. V. 2010 03.–04.12.2010
55 Kronowitz SJ. Delayed-immediate breast reconstruction. Plast Reconstr Surg 2004; 113: 1617-1628
56 Schmutzler R. Das hereditäre Mamma-Carcinom: Genetik und Prävention. In: AGO State of the Art. München: W. Zuckschwerdt Verlag; 2009: 201
57 Lostumbo L, Ezzo J et al. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev; 2004 CD002748 18.
58 Metcalfe KA, Narod SA et al. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA 1 or BRCA 2 mutation. Clin Genet 2008; 73: 474-947
59 Grann VR. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive and BRCA2-positive patients. J Clin Oncol 1998; 16: 979-985
60 Isern AE, Ringberg A et al. Aesthetic outcome, patient satisfaction, and health related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction. J Plast Reconstr Aesthet Surg 2008; 61: 11177-11187
61 Newman LA. Prophylactic mastectomy. J Am Coll Surg 2000; 191: 322-330
62 Rezai M. Reduktionsplastik mit modifizierter inferiorer Technik. In: Granitzka S, Siebert W. Plastische Operationen an der weiblichen Brust. 2.. Aufl. München: H. Marseille; 2007
63 Kern P, Krämer S, Rezai M. Brustrekonstruktion nach prophylaktischer Mastektomie. J Ästhet Chir 2010; 3: 136-141
64 Petit JY. Breast reconstruction techniques in cancer patients: which ones, when to apply, which immediate and long term risks. Crit Rev Oncol 2001; 38: 231-239
65 Zhong T, Antony A, Cordeiro P. Surgical outcomes and nipple projection using the modified skate flap for nipple-areola reconstruction in a series of 422 implant reconstructions. Ann Plast Surg 2009; 62: 591-595
66 Spear SL. Prophylactic mastectomy: indications, options, and reconstructive alternatives. Plast Reconstr Surg 2005; 115: 891-909